


Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial

Matthias Stelljes,¹ Dietrich W. Beelen,² Jan Braess,³ Maria C. Sauerland,⁴ Achim Heinecke,⁴ Björna Berning,¹ Hans J. Kolb,³ Ernst Holler,⁵ Rainer Schwerdtfeger,⁶ Renate Arnold,⁷ Karsten Spiekermann,³ Carsten Müller-Tidow,¹ Hubert L. Serve,¹ Gerda Silling,¹ Wolfgang Hiddemann,³ Wolfgang E. Berdel,¹ Thomas Büchner,¹ and Joachim Kienast¹ on behalf of the German AML Cooperative Group (AMLCG)

¹Department of Medicine A/Hematology and Oncology, University of Muenster, Muenster; ²Department of Bone Marrow Transplantation, University Hospital of Essen, Essen; ³Department of Internal Medicine III, University of Munich-Grosshadern, Munich; ⁴Institute of Biostatistics and Clinical Research, University of Muenster, Muenster; ⁵Department of Hematology and Oncology, University of Regensburg, Regensburg; ⁶Centre for Bone Marrow and Blood Stem Cell Transplantation, Deutsche Klinik für Diagnostik, Wiesbaden, and ⁷Department of Hematology and Oncology, Charité, Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany

Citation: Stelljes M, Beelen DW, Braess J, Sauerland MC, Heinecke A, Berning B, Kolb HJ, Holler E, Schwerdtfeger R, Arnold R, Spiekermann K, Müller-Tidow C, Serve HL, Silling G, Hiddemann W, Berdel WE, Büchner T, and Kienast J on behalf of the German AML Cooperative Group (AMLCG). Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial. *Haematologica* 2011;96(7):972-979. doi:10.3324/haematol.2011.041004

Online Supplementary Figure S1. Distribution of patients within the AMLCG99 multicenter study cohort. All 35 control patients included had a relapse-free survival of at least 90 days from CR1 in order to account for the median time from CR1 to transplantation in HCT comparison groups (88 days).



HCT, hematopoietic stem cell transplantation; CR1, first complete remission; MRD, matched related donor; MUD, matched unrelated donor; RFS ≥90 days, relapse-free survival ≥90 days from entry into CR1. *35 out of 56 patients not receiving allogeneic HCT in CR1 had a RFS ≥90 days and we, therefore, were eligible for a landmark comparison. Twenty-one patients relapsed within 90 days after achieving CR1. #For the "intent to treat" analysis, 4/35 control patients with identified donors were included in the group "HCT from MUD" (n=1) or "HCT from MRD" (n=3), seven patients had contraindications to allogeneic HCT (no donor search initiated) and were excluded from the "intent to treat" analysis.